PIAS3 expression in squamous cell lung cancer is low and predicts overall survival

Cancer Medicine

Volumn 4, Issue 3, 2015, Pages 325-332

  Abbas, Rime ^a   Mccoll, Karen S ^b   Kresak, Adam ^b   Yang, Michael ^b   Chen, Yanwen ^b   Fu, Pingfu ^b   Wildey, Gary ^b   Dowlati, Afshin ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

PIAS3; Squamous cell lung cancer; STAT3; Survival

Indexed keywords

CURCUMIN; STAT3 PROTEIN; CHAPERONE; MESSENGER RNA; PIAS3 PROTEIN, HUMAN; PROTEIN INHIBITOR OF ACTIVATED STAT;

ARTICLE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL LUNG CARCINOMA; CELL LINE; GENETICS; LUNG TUMOR; METABOLISM; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TUMOR; CURCUMIN; HUMANS; LUNG NEOPLASMS; MOLECULAR CHAPERONES; PROGNOSIS; PROTEIN INHIBITORS OF ACTIVATED STAT; RNA, MESSENGER;

EID: 84979856668     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.372     Document Type: Article

References (23)

1. Siegel, R., J. Ma, Z. Zou, and A. Jemal . 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64:9-29.
2. Drilon, A., N. Rekhtman, M. Ladanyi, and P. Palik . 2012. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 13:e418-e426.
3. Li, T., H.-J. Kung, P. C. Mack, and D. R. Gandara . 2013. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J. Clin. Oncol. 31:1039-1049.
4. Reck, M., D. F. Heigener, T. Mok, J. C. Soria, and K. F. Rabe . 2013. Management of non-small-cell lung cancer: recent developments. Lancet 382:709-719.
5. Rosell, R., T. G. Bivona, and N. Karachaliou . 2013. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382:720-723.
6. Raparia, K., C. Villa, M. M. DeCamp, J. D. Patel, and M. P. Mehta . 2013. Molecular profiling in non-small cell lung cancer. A step towards personalized medicine. Arch. Pathol. Lab. Med. 137:481-491.
7. Gold, K. A., I. I. Wistuba, and E. S. Kim . 2012. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin. Cancer Res. 18:3002-3007.
8. Sos, M. L., and R. K. Thomas . 2012. Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene 31:4811-4814.
9. Schindler, C. W. 2002. JAK-STAT signaling in human disease. J. Clin. Invest. 109:1133-1137.
10. Miklossy, G., T. S. Hilliard, and J. Turkson . 2013. Therapeutic modulators of STAT signaling for human diseases. Nat. Rev. Drug Discov. 12:611-629.
11. Quintas-Cardama, A., and S. Verstovsek . 2013. Molecular pathways: JAK-STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res. 19:1933-1940.
12. Chung, C. D., J. Liao, B. Lui, X. Rao, P. Jay, P. Berta, et al. 1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:1803-1805.
13. Sharrocks, A. D. 2006. PIAS proteins and transcriptional regulation- more than just SUMO E3 ligases? Genes Dev. 20:754-759.
14. Brantley, E. C., L. B. Nabors, G. Y. Gillespie, Y. H. Choi, C. A. Palmer, K. Harrison, et al. 2008. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expression. Clin. Cancer Res. 14:4694-4704.
15. Kluge, A., S. Dabir, I. Vlassenbroeck, R. Eisenberg, and A. Dowlati . 2011. Protein inhibitor of activated STAT3 expression in lung cancer. Mol. Oncol. 5:256-264.
16. Dabir, S., A. Kluge, K. McColl, Y. Liu, M. Lam, B. Halmos, et al. 2013. PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int. J. Cancer 134:1045-1054.
17. The Cancer Genome Atlas Research Network. 2012. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-525.
18. Shehzad, A., F. Wahid, and Y. S. Lee . 2010. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. Chem. Life Sci. 9:489-499.
19. Kunnumakkara, A., P. Anand, and B. B. Aggarwal . 2008. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269:199-225.
20. Bill, M. A., J. R. Fuchs, C. Li, J. Yui, C. Bakan, D. M. Benson Jr, et al. 2010. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol. Cancer. 9:165.
21. Saydmohammed, M., D. Joseph, and V. Syed . 2010. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J. Cell. Biochem. 110:447-456.
22. Yang, C.-L., Y.-Y. Liu, Y.-G. Ma, Y.-X. Xue, D.-G. Liu, Y. Ren, et al. 2012. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signaling pathway. PLoS ONE 7:e37960.
23. Anand, P., A. B. Kunnumakkara, R. A. Newman, and B. B. Aggarwal . 2007. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4:807-818.